| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2077286 | Cell Stem Cell | 2015 | 5 Pages |
Abstract
Induced pluripotent stem cells (iPSCs) have the potential to transform drug discovery and healthcare in the 21st century. However, successful commercialization will require standardized manufacturing platforms. Here we highlight the need to define standardized practices for iPSC generation and processing and discuss current challenges to the robust manufacture of iPSC products.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Marli Silva, Laurence Daheron, Hannah Hurley, Kim Bure, Richard Barker, Andrew J. Carr, David Williams, Hae-Won Kim, Anna French, Pete J. Coffey, Justin J. Cooper-White, Brock Reeve, Mahendra Rao, Evan Y. Snyder, Kelvin S. Ng, Benjamin E. Mead,